YpsoDot – The 2-step fixed-dose pen delivering up to 1 mL
YpsoDot is a fixed-dose, pull-and-push pen supporting patients with a clear, confirmed sequence designed to facilitate correct use from the first injection.
1 mL
maximum fixed dose per injection
2
active steps: pull, then push
Fewer
devices per monthly regimen
Effortless simplicity by design
A simplified device profile is a commercial and regulatory asset. A lower use-error profile is designed to reduce the burden of Human Factors studies, support a stronger combination product dossier, and give HCP training programs a shorter, more scalable path. In a market where payers increasingly tie reimbursement to adherence evidence, device simplicity becomes a differentiator on label, in HTA submissions, and in market access negotiations.
- Two active steps for fixed-dose injection sequence: pull & push
- Pull-to-load mechanism eliminates dose dialing at source
- Active dose-stop mechanically prevents over-delivery
- Visual and tactile confirmation cues at both load and inject steps
- No priming step, reducing handling complexity and drug waste while simplifying and speeding up final assembly
- Simplified HCP training for shorter, more scalable instruction pathway
Handling steps Simply pull and push
A simplified device profile is a commercial and regulatory asset. A lower use-error profile is designed to reduce the burden of Human Factors studies, support a stronger combination product dossier, and give HCP training programs a shorter, more scalable path. In a market where payers increasingly tie reimbursement to adherence evidence, device simplicity becomes a differentiator on label, in HTA submissions, and in market access negotiations.
No priming step Ready to use
Reduces handling complexity, eliminates drug waste, and simplifies final assembly for manufacturing partners.
Fixed-dose delivery up to 1.0 mL
Next-generation therapies are pushing beyond what conventional pens can deliver, in dose volume and in formulation complexity. Selecting the right delivery platform is not just a procurement choice; it establishes the foundation for your product’s entire commercial lifecycle. This is a strategic decision that impacts long-term success.
- Fixed-dose range 0.2-1.0 mL, covering the next-gen biologics dose spectrum
- Supports high-viscosity biologics beyond standard aqueous formulations
- Pre-filled, ready-to-use: no patient cartridge handling or loading
- Platform architecture enables dose variants across the therapy lifecycle without device redesign
Multi-use, mono-material built for the circular economy
The injection device industry generates tens of millions of discarded injectors every year. YpsoDot was designed to reduce that burden – and to give pharma partners a sustainability argument that runs from the ESG report to the market access dossier.
- Mono-material construction: single recyclable polymer stream
- Bio-based plastic reduces reliance on virgin fossil-derived polymer
- Multi-use cartridge: one YpsoDot offers the option to replace multiple disposable autoinjectors per monthly regimen
- Reduced CO2 per injection (vs. comparable platforms)
Dimensions and specifications Facts and figures
- Primary containerStandard 3 mL cartridge according to ISO 11608-31
- DosingFixed
- Number of doses3 to 15
- Min. dose0.2 mL2
- Max. dose1 mL2
- Dose indicationsVisual and tactile confirmation cues
- Compatible needle typeCompatible with standard and safety pen needles3
- ComplianceISO 11608-1, ISO 11608-5, ISO 14001, EU, FDA
- MaterialsMono-material, bio-based polymer
1 3 mL cartridge inner diameter of 9.7 mm recommended
2 Dose configurations between 0.2-1 mL are possible (e.g. 0.75 mL)
3 Pen needles according to ISO 11608-2
Ready to explore YpsoDot for your pipeline?
If you’d like more information or have a specific request, simply fill out the form below and our team will get back to you as soon as possible.
Resources & expert insights on YpsoDot
